Gsa Capital Partners LLP Esperion Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$1.84 - $3.24 $670,256 - $1.18 Million	364,270 Added 81.11%	813,399 $1.81 Million
Q1 2024 May 03, 2024	SELL	$2.02 - $3.02 $1.37 Million - $2.05 Million	-679,020 Reduced 60.19%	449,129 $1.2 Million
Q4 2023 Feb 16, 2024	BUY	$0.73 - $3.08 $8,390 - $35,401	11,494 Added 1.03%	1,128,149 $3.37 Million
Q3 2023 Nov 15, 2023	BUY	$0.96 - $1.79 $658,303 - $1.23 Million	685,733 Added 159.13%	1,116,655 $1.09 Million
Q2 2023 Aug 14, 2023	BUY	$1.2 - $1.76 $382,005 - $560,274	318,338 Added 282.76%	430,922 $598,000
Q1 2023 May 12, 2023	BUY	$1.46 - $7.3 $137,775 - $688,879	94,367 Added 518.02%	112,584 $179,000
Q4 2022 Feb 13, 2023	BUY	$5.09 - $8.5 $92,724 - $154,844	18,217 New	18,217 $113,000
Q4 2021 Feb 14, 2022	SELL	$4.81 - $11.92 $113,650 - $281,645	-23,628 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$11.34 - $21.37 $267,941 - $504,930	23,628 New	23,628 $285,000
Q1 2021 May 10, 2021	SELL	$25.12 - $36.89 $504,736 - $741,230	-20,093 Closed	0 $0
Q4 2020 Feb 03, 2021	BUY	$24.2 - $35.76 $170,440 - $251,857	7,043 Added 53.97%	20,093 $522,000
Q3 2020 Nov 06, 2020	BUY	$31.18 - $52.71 $406,899 - $687,865	13,050 New	13,050 $485,000
Q3 2019 Nov 12, 2019	SELL	$34.47 - $47.53 $523,840 - $722,313	-15,197 Closed	0 $0
Q2 2019 Aug 06, 2019	BUY	$40.1 - $52.33 $609,399 - $795,259	15,197 New	15,197 $707,000
Q4 2017 Feb 14, 2018	SELL	$43.47 - $67.43 $393,403 - $610,241	-9,050 Closed	0 $0
Q3 2017 Nov 20, 2017	BUY	$43.8 - $52.77 $396,390 - $477,568	9,050	9,050 $454,000

207

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $168M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.